Last viewed:
BTX
Prices are updated after-hours
BTX
4
|
$4.102
-93.91%
|
Information
(0.0% 1d)
(0.0% 1m)
(0.0% 1y)
(0.0% 2d)
(2.5% 3d)
(0.0% 7d)
(768.24%
volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 241,303,181
https://brooklynitx.com
Sec
Filling
|
Patents
| 2018 employees
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus.
Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
cancer
t-cell
msa
ceiling
add to watch list
Paper trade
email alert is off
Press-releases
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results
Published: 2021-11-09
(Crawled : 22:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -97.75%
| O: -1.65%
H: 1.56%
C: -9.71%
financial results
results
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
Published: 2021-10-14
(Crawled : 21:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -97.75%
| O: 3.62%
H: 0.0%
C: -3.17%
nasdaq
Brooklyn ImmunoTherapeutics Reports Inducement Grants
Published: 2021-09-23
(Crawled : 21:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -97.96%
| O: -1.59%
H: 2.41%
C: -4.05%
granted
report
grant
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
Published: 2021-09-22
(Crawled : 14:15)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -97.87%
| O: 0.62%
H: 1.75%
C: 0.31%
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
Published: 2021-09-21
(Crawled : 13:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -98.26%
| O: -12.87%
H: 0.63%
C: -6.32%
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
Published: 2021-09-13
(Crawled : 13:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -98.33%
| O: -0.33%
H: 11.54%
C: 3.76%
conference
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
Published: 2021-08-20
(Crawled : 21:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| Email alert
Add to watchlist
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
Published: 2021-08-20
(Crawled : 13:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -97.69%
| O: 1.58%
H: 7.44%
C: 6.67%
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
Published: 2021-08-16
(Crawled : 23:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| -98.08%
| O: -4.58%
H: 7.93%
C: 3.92%
conference
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
Published: 2021-08-13
(Crawled : 19:00)
- globenewswire.com
BTX
4
|
$4.102
-93.91%
|
Information
| Email alert
Add to watchlist
conference
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001104659-23-095434
4
2023-08-25
2023-07-13
Buy
P
2307692
2307692